Single Patient Investigational Treatment for Cree Leukoencephalopathy

NCT ID: NCT07300397

Last Updated: 2025-12-23

Basic Information

• Recruitment Status: ENROLLING_BY_INVITATION
• Clinical Phase: NA
• Total Enrollment: 1 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-12-03
• Study Completion Date: 2029-01-03

Brief Summary

Cree Leukoencephalopathy (CLE) is a very rare and severe brain disease that mainly affects members of the Cree communities in Northern Quebec. It causes the white matter of the brain-the part that helps nerves communicate-to slowly break down. As the disease progresses, children develop serious neurological problems that worsen over time and, sadly, lead to early death. At the moment, there are no effective treatments for CLE. The disease is caused by a single genetic change in the EIF2B5 gene, the same gene involved in another related condition called Vanishing White Matter (VWM).

A new medication called fosigotifator (FGT, ABBV-CLS-7262) is currently being tested in an international clinical trial for VWM.

The goal of this study is to provide access to this investigational medication (FGT) for a patient with CLE/VWM for whom no other treatment options exist. The study will also look at whether the potential benefits of FGT outweigh the risks, and whether the drug might slow down or stop the brain's white matter from deteriorating. By targeting the underlying cause of the disease, FGT may help reduce neurological symptoms and improve the patient's quality of life.

Detailed Description

Cree Leukoencephalopathy (CLE) is a rare and fatal neurodegenerative disorder predominantly affecting the Cree population in Northern Quebec. Characterized by progressive white matter degeneration, this condition leads to severe neurological impairment and decline, leading to premature death. Despite its significant impact on the affected population, there are currently no effective treatments for CLE. CLE is caused by a single founder pathogenic variant in the EIF2B5 gene and is therefore allelic to VWM.

Fosigotifator (FGT, ABBV-CLS-7262) has been developed and its safety and efficacy are currently being studied in a multi-center Phase 1b/2 clinical trial for Vanishing White Matter (VWM) by Calico.

This study aims to provide access to an investigational drug (FGT) for a patient diagnosed with CLE/VWM disease for whom there are no other treatment options available. The study will also evaluate the risk/benefit of FGT in slowing or halting the progression of white matter degeneration in this patient with CLE. By targeting the underlying pathophysiological mechanisms of white matter damage, FGT is expected to alleviate neurological symptoms and improve the quality of life for the patient.

Conditions

Cree Leukoencephalopathy

Keywords

N=1; Cree Leukoencephalopathy; Fosigotifator

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Single patient trial

Fosigotifator

Group Type: EXPERIMENTAL

Fosigotifator

Intervention Type: DRUG

Fosigotifator

Interventions

Fosigotifator

Fosigotifator

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• • Molecularly confirmed diagnosis of CLE

• Pre-symptomatic or early symptomatic patient
• Signed informed consent from the Legal Guardians/caregivers (parents)
• Must not be eligible for any actively enrolling trial of fosigotifator in CLE/VWM
• Must be at least 1 month of age at the Baseline visit
• Must weigh at least 5kg at the Baseline visit

Exclusion Criteria

• N/A

• Minimum Eligible Age: 1 Month
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Genevieve Bernard

OTHER

Sponsor Role: lead

Responsible Party

Genevieve Bernard

MD, MSc, FRCPc

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

McGill University Health Centre

Montreal, Quebec, Canada

Countries

Canada

Other Identifiers

CLE02-ABBV-CLS-7262

Identifier Type: -

Identifier Source: org_study_id